尤瑞克林联合双抗血小板治疗进展性脑梗死的疗效观察

The effect of urinary kallidinogenase combined with dual antiplatelet therapy on progressive cerebral infarction

目的：观察尤瑞克林联合双抗血小板治疗进展性脑梗死的疗效及安全性。方法：选取2012-08~2014-12我院收治的进展性脑梗死患者67例,将其随机分为试验组33例和对照组34例,试验组用尤瑞克林联合阿司匹林和氯吡格雷治疗,对照组用阿司匹林联合氯吡格雷治疗,治疗14d,并在治疗前、后分别评价神经功能缺损程度（NIHSS）,日常生活活动能力（ADL）和临床疗效。结果：试验组总有效率为87.9%,高于对照组的67.6%,两组差异有统计学意义（χ2=3.945,P〈0.05）;治疗14d后试验组NIHSS低于对照组（P〈0.05）,ADL评分高于对照组（P〈0.05）。两组均未见严重不良反应发生。结论：尤瑞克林联合阿司匹林和氯吡格雷治疗进展性脑梗死疗效显著,安全性好。

Objective： To observe the efficacy and safety of urinary kallidinogenase combined with dual antiplatelet therapy on progressive cerebral infarction. Methods： 67 patients with progressive cerebral infarction admitted to our hospital from August 2012 to December 2014 were randomly divided into two groups： 33 patients in trial group were treated by urinary kallidinogenase combined with aspirin and clopidogrel,while the other 34 patients in control group were treated by aspirin and clopidogrel. The course of treatment lasted 14 days. The following indications were assessed before and after the treatment respectively： the national institutes of health stroke scale（ NIHSS）,activities of daily living（ ADL）,and clinical effects. Results： The total effective rate of the trial group was87. 9%,was higher than that in control group of 67. 6%,with significant differences（ χ2= 3. 945,P〈0. 05）. 14 days after treatment,the scores of NIHSS in the trial group was lower than that of control group（ P〈0. 05）. The scores of ADL in the trial group was higher than that of control group（ P〈0. 05）. There were no obvious adverse reactions in both groups. Conclusion： Urinary kallidinogenase combined with aspirin and clopidogrel in treating progressive cerebral infarction have significant efficiency and safety.